ANGPTL3 Inhibition in Homozygous Familial Hypercholesterolemia

N Engl J Med. 2017 Jul 20;377(3):296-297. doi: 10.1056/NEJMc1705994.

Authors

Daniel Gaudet¹, Daniel A Gipe², Robert Pordy², Zahid Ahmad³, Marina Cuchel⁴, Prediman K Shah⁵, Kuang-Yuh Chyu⁵, William J Sasiela², Kuo-Chen Chan², Diane Brisson¹, Etienne Khoury¹, Poulabi Banerjee², Viktoria Gusarova², Jesper Gromada², Neil Stahl², George D Yancopoulos², G Kees Hovingh⁶

Affiliations

¹ Université de Montréal, Chicoutimi, QC, Canada.
² Regeneron Pharmaceuticals, Tarrytown, NY.
³ University of Texas Southwestern Medical Center, Dallas, TX.
⁴ Perelman School of Medicine of University of Pennsylvania, Philadelphia, PA.
⁵ Cedars-Sinai Heart Institute, Los Angeles, CA.
⁶ University of Amsterdam, Amsterdam, the Netherlands.

PMID: 28723334
DOI: 10.1056/NEJMc1705994

No abstract available

Publication types

Clinical Trial
Letter

MeSH terms

Angiopoietin-Like Protein 3
Angiopoietin-like Proteins
Angiopoietins / antagonists & inhibitors*
Antibodies, Monoclonal / therapeutic use*
Cholesterol, LDL / blood*
Genotype
Humans
Hyperlipoproteinemia Type II / blood
Hyperlipoproteinemia Type II / drug therapy*
Hyperlipoproteinemia Type II / genetics
Receptors, LDL / drug effects
Receptors, LDL / genetics
Receptors, LDL / metabolism

Substances

ANGPTL3 protein, human
Angiopoietin-Like Protein 3
Angiopoietin-like Proteins
Angiopoietins
Antibodies, Monoclonal
Cholesterol, LDL
Receptors, LDL
evinacumab